RESEARCHER PROFILE
Jason Rogers (Filmed April 2024)
Postdoctoral Fellow
Menzies Institute for Medical Research,
University of Tasmania
Jason Rogers is a Tasmanian physiotherapist clinician-researcher with a longstanding interest in improving musculoskeletal foot and ankle conditions. He completed his PhD at the Menzies Institute for Medical Research at the University of Tasmania in 2022 investigating the clinical and imaging factors associated with a common foot complaint known as chronic plantar heel pain.
Chronic plantar heel pain, historically known as plantar fasciitis, is common and commonly recalcitrant, yet the optimal treatment for this condition is not clear. The focus of Jason’s postgraduate research is on improving treatment pathways for chronic plantar heel pain. In particular his research has identified that there are many different sub-groups of plantar heel pain that may warrant specific and individualised treatment approaches. For example his research found that up to half of people with this condition have a type of bone bruise or stress response in the heel known as a ‘bone marrow lesion’ (BML). His BALSA trial will test the effectiveness of targeting these lesions with a bone-sensitive treatment known as shockwave therapy, comparing pain and BML size outcomes against a sham shockwave control group.
As well as improving treatment outcomes for this specific and sizeable sub-group of heel pain sufferers, this research will help inform the future of targeted care treatment approaches for plantar heel pain.
-
Personalised approaches to lung therapy
Dr. Adams’ research focus is on lung cancer, which is the deadliest of all cancers worldwide. He is working towards developing personalised approaches to pinpoint a therapy that is going to be most effective for the person with that disease. Dr. Adams’ research is focusing on chemotherapy and targeted therapy, and he is trying to identify upfront which of those tumours are likely to be resistant to the therapy. He then identifies strategies that will resensitize or increase the sensitivity of the tumour to the standard of care that is targeted therapy or chemotherapy.
-
Discovery of RANK Ligand’s role in bone metabolism and the immune system to treat osteoporosis
Emeritus Professor Jack Martin’s research began a discovery cascade that led to the identification of a new protein and the development of a novel and effective drug therapy that is now used worldwide to treat osteoporosis, cancer and other diseases.
-
Development of novel analytical and diagnostic tools using nanotechnology and microfluidics
Dr Alain Wuethrich is an NHMRC Emerging Leader fellow and ARC DECRA awardee at the Australian Institute for Bioengineering and Nanotechnology.
Hailing from Switzerland, research focuses on the development of novel analytical and diagnostic tools that harness nanotechnology and microfluidics; two rapidly growing fields with high potential to provide diagnostic solutions needed for precision medicine.
